| Business Summary | | Vyrex
Corporation
is
a
research
and
development
stage
company
seeking
to
discover
and
develop
pharmaceuticals
and
nutraceuticals
for
the
treatment
and
prevention
of
respiratory,
cardiovascular
and
neurodegenerative
diseases
and
conditions
associated
with
aging.
The
Company's
research
has
been
focused
on
targeted
antioxidant
therapeutics
for
respiratory,
neurological
and
cardiovascular
diseases
and
the
development
of
nutraceuticals
for
the
dietary
support
of
certain
age-related
conditions.
Vantox
is
currently
the
Company's
lead
drug
candidate.
The
Company's
research
with
Vantox
indicates
it
may
have
usefulness
in
the
treatment
of
asthma,
ARDS,
cystic
fibrosis,
oxygen
toxicity,
smoke
inhalation
and
other
respiratory
diseases
and
conditions. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Vyrex
Corp.
is
engaged
in
the
discovery
and
development
of
biopharmaceuticals
for
treatment
and
prevention
of
various
disorders
including
AIDS,
respiratory
diseases,
cancer
and
aging.
For
the
six
months
ended
6/30/01,
revenues
fell
96%
to
$849.
Net
loss
fell
73%
to
$71
thousand.
Revenues
reflect
decreased
licensing
and
royalty
income.
Lower
loss
reflects
the
reversal
of
previously
accrued
R&D
expenses
and
decreased
consulting
expenses. | More
from
Market Guide: Significant
Developments |
| | |
| Position | Sheldon Hendler, Ph.D., M.D., 64 | Chairman | G. Dale Garlow, 59 | Pres,
CEO, Director |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|